We measured FGF23 using both intact and c-terminal assays and performed a detailed analysis of a wide range of parameters that are involved in iron metabolism and inflammation as well as endogenous EPO, which, to the best of our knowledge, has never been analyzed before in the context of FGF23′s role in anemia in human CKD. This evidence concerns the gene EPO and chronic kidney disease.